Biotinidase deficiency presenting as Neuromyelitis Optica Spectrum Disorder

2020 ◽  
Vol 42 (10) ◽  
pp. 762-766
Author(s):  
Snehal Shah ◽  
Najm Khan ◽  
Rahul Lakshmanan ◽  
Barry Lewis ◽  
Lakshmi Nagarajan
Keyword(s):  
Neuromyelitis Optica ◽  
Biotinidase Deficiency ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder

A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency

2017 ◽  
Vol 32 (3) ◽  
pp. 675-678 ◽  
Author(s):  
Sanem Yilmaz ◽  
Mine Serin ◽  
Ebru Canda ◽  
Cenk Eraslan ◽  
Hande Tekin ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Vision Loss ◽  
Late Onset ◽  
Biotinidase Deficiency ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder

scholarly journals Neuromyelitis optica spectrum disorder with deafness and an extensive brainstem lesion

Heliyon ◽  
2021 ◽  
Vol 7 (1) ◽  
pp. e06106
Author(s):  
Asako Onda ◽  
Mikihiro Yamazaki ◽  
Takashi Shimoyama ◽  
Hiroshi Yaguchi
Keyword(s):  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Brainstem Lesion

Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study

2021 ◽  
Vol 204 ◽  
pp. 106606
Author(s):  
Samaneh Haji Molla Rabi ◽  
Shaghayegh Shahmirzaei ◽  
Mohammad Ali Sahraian ◽  
Razieh Sadat Kazemi Mozdabadi ◽  
Hossein Rezaei Aliabadi ◽  
...  
Keyword(s):  
Sleep Disorders ◽  
Neuromyelitis Optica ◽  
Case Control Study ◽  
Case Control ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Control Study

scholarly journals The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhila Maghbooli ◽  
Abdorreza Naser Moghadasi ◽  
Nasim Rezaeimanesh ◽  
Abolfazl Omidifar ◽  
Tarlan Varzandi ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Neuromyelitis Optica ◽  
Serum Levels ◽  
Spectrum Disorder ◽  
Control Group ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Downstream Signaling ◽  
Reduce Insulin Sensitivity ◽  
Circulating Levels

Abstract Background Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity. Methods We aimed to determine the risk association of hyperinsulinemia in NMOSD patients with seropositive AQP4-IgG and the serum levels of interleukin (IL)-6 and IL-17A compared with the control group. Serum levels of metabolic (Insulin, Fasting Blood Sugar (FBS), lipid profile) and inflammatory (IL-6 and IL-17) markers were assessed in 56 NMOSD patients and 100 controls. Results Hyperinsulinemia was more prevalent in NMOSD patients independent of age, sex and body mass index (BMI) (48.2% vs. 26%, p = 0.005) compared to control group. After adjusting age, sex and BMI, there was significant association between lower insulin sensitivity (IS) and NMOSD risk (95% CI: Beta = 0.73, 0.62 to 0.86, p = 0.0001). Circulating levels of IL-6 and IL-17 were higher in NMOSD patients, and only IL-6 had an effect modifier for the association between lower insulin sensitivity and NMOSD risk. Conclusions Our data suggests that inflammatory pathogenesis of NMOSD leads to hyperinsulinemia and increases the risk of insulin resistance.

scholarly journals Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

2021 ◽  
Vol 47 ◽  
pp. 102641
Author(s):  
Jacqueline Palace ◽  
Dean M. Wingerchuk ◽  
Kazuo Fujihara ◽  
Achim Berthele ◽  
Celia Oreja-Guevara ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Phase 3 ◽  
Randomized Controlled ◽  
Subgroup Analyses ◽  
Prevent Trial
Sign in / Sign up

Export Citation Format

Share Document